CXCL16 and oxLDL are induced in the onset of diabetic nephropathy

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 9 B, 2009, Pages 3809-3825

  Gutwein, Paul ^a   Abdel Bakky, Mohamed Sadek ^a   Doberstein, Kai ^a   Schramme, Anja ^b   Beckmann, Janet ^a   Schaefer, Liliana ^a   Amann, Kerstin ^c   Doller, Anke ^a   Kämpfer Kolb, Nicole ^a   Abdel Aziz, Abdel Aziz H ^d   El Sayed, El Sayed M ^d   Pfeilschifter, Josef ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d AL AZHAR UNIVERSITY   (Egypt)

Author keywords

ADAM10; CXCL16; Diabetic nephropathy; Podocytes; Primary tubular cells

Indexed keywords

ADAM PROTEIN; ADAM10 PROTEIN, HUMAN; ADAM10 PROTEIN, MOUSE; ALPHA CHEMOKINE; ALPHA3 INTEGRIN; CD36 ANTIGEN; CXCL16 PROTEIN, HUMAN; CXCL16 PROTEIN, MOUSE; GRANULOCYTE CHEMOTACTIC PROTEIN 2; LOW DENSITY LIPOPROTEIN; MEMBRANE PROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR; SECRETASE;

AGED; ANIMAL; ARTICLE; BIOSYNTHESIS; DIABETIC NEPHROPATHY; EXPERIMENTAL DIABETES MELLITUS; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HYPERGLYCEMIA; KIDNEY TUBULE; MALE; METABOLISM; MIDDLE AGED; MOUSE; PATHOLOGY; TREATMENT OUTCOME;

ADAM PROTEINS; AGED; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTIGENS, CD36; CHEMOKINE CXCL6; CHEMOKINES, CXC; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYPERGLYCEMIA; INTEGRIN ALPHA3; KIDNEY TUBULES; LIPOPROTEINS, LDL; MALE; MEMBRANE PROTEINS; MICE; MIDDLE AGED; RECEPTORS, SCAVENGER; TREATMENT OUTCOME;

MUS;

EID: 77449083883     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00761.x     Document Type: Article

References (57)

1. Gin H, Rigalleau V, Aparicio M. Lipids, protein intake, and diabetic nephropathy. Diabetes Metab. 2000, 26:45-53.
2. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes. 2008, 57:1446-54.
3. Deslypere JP. Modified lipoproteins in diabetes. J Intern Med Suppl. 1994, 736:69-74.
4. Lyons TJ. Oxidized low density lipoproteins: a role in the pathogenesis of atherosclerosis in diabetes. Diabet Med. 1991, 8:411-9.
5. Lee HS. Oxidized LDL, glomerular mesangial cells and collagen. Diabetes Res Clin Pract. 1999, 45:117-22.
6. Nishida Y, Oda H, Yorioka N. Effect of lipoproteins on mesangial cell proliferation. Kidney Int Suppl. 1999, 71:S51-3.
7. Wheeler DC, Chana RS, Topley N. Oxidation of low density lipoprotein by mesangial cells may promote glomerular injury. Kidney Int. 1994, 45:1628-36.
8. Claise C, Edeas M, Chaouchi N. Oxidized-LDL induce apoptosis in HUVEC but not in the endothelial cell line EA.hy 926. Atherosclerosis. 1999, 147:95-104.
9. Kamanna VS, Pai R, Ha H. Oxidized low-density lipoprotein stimulates monocyte adhesion to glomerular endothelial cells. Kidney Int. 1999, 55:2192-202.
10. Bussolati B, Deregibus MC, Fonsato V. Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway. J Am Soc Nephrol. 2005, 16:1936-47.
11. Witztum JL, Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans. Trends Cardiovasc Med. 2001, 11:93-102.
12. Akiba S, Chiba M, Mukaida Y. Involvement of reactive oxygen species and SP-1 in fibronectin production by oxidized LDL. Biochem Biophys Res Commun. 2003, 310:491-7.
13. Brune B, Zhou J, von Knethen A. Nitric oxide, oxidative stress, and apoptosis. Kidney Int Suppl. 2003, S22-4.
14. Chade AR, Mushin OP, Zhu X. Pathways of renal fibrosis and modulation of matrix turnover in experimental hypercholesterolemia. Hypertension. 2005, 46:772-9.
15. Reddy S, Santanam N, Reddy PP. Interaction of Interceed oxidized regenerated cellulose with macrophages: a potential mechanism by which Interceed may prevent adhesions. Am J Obstet Gynecol. 1997, 177:1315-20.
16. Ding G, van Goor H, Ricardo SD. Oxidized LDL stimulates the expression of TGF-beta and fibronectin in human glomerular epithelial cells. Kidney Int. 1997, 51:147-54.
17. Gruden G, Perin PC, Camussi G. Insight on the pathogenesis of diabetic nephropathy from the study of podocyte and mesangial cell biology. Curr Diabetes Rev. 2005, 1:27-40.
18. Kanwar YS, Wada J, Sun L. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med. 2008, 233:4-11.
19. Dalla VM, Masiero A, Roiter AM. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes. 2003, 52:1031-5.
20. Pagtalunan ME, Miller PL, Jumping-Eagle S. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997, 99:342-8.
21. Steffes MW, Schmidt D, McCrery R. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int. 2001, 59:2104-13.
22. White KE, Bilous RW, Marshall SM. Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes. 2002, 51:3083-9.
23. Kita T, Kume N, Minami M. Role of oxidized LDL in atherosclerosis. Ann N Y Acad Sci. 2001, 947:199-205.
24. Zingg JM, Ricciarelli R, Azzi A. Scavenger receptors and modified lipoproteins: fatal attractions. IUBMB Life. 2000, 49:397-403.
25. Shimaoka T, Kume N, Minami M. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J Biol Chem. 2000, 275:40663-6.
26. Shimaoka T, Nakayama T, Fukumoto N. Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells. J Leukoc Biol. 2004, 75:267-74.
27. Abel S, Hundhausen C, Mentlein R. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol. 2004, 172:6362-72.
28. Gough PJ, Garton KJ, Wille PT. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J Immunol. 2004, 172:3678-85.
29. Geissmann F, Cameron TO, Sidobre S. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol. 2005, 3:e113.
30. Matloubian M, David A, Engel S. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol. 2000, 1:298-304.
31. Okamura DM, Lopez-Guisa JM, Koelsch K. Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury. Am J Physiol Renal Physiol. 2007, 293:F575-85.
32. Saleem MA, O'Hare MJ, Reiser J. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol. 2002, 13:630-8.
33. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001, 25:402-8.
34. Schaefer L, Tsalastra W, Babelova A. Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and mammalian target of rapamycin. Am J Pathol. 2007, 170:301-15.
35. Susztak K, Ciccone E, McCue P. Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med. 2005, 2:e45.
36. Schramme A, Abdel-Bakky MS, Gutwein P. Characterization of CXCL16 and ADAM10 in the normal and transplanted kidney. Kidney Int. 2008, 74:328-38.
37. Li C, Ruotsalainen V, Tryggvason K. CD2AP is expressed with nephrin in developing podocytes and is found widely in mature kidney and elsewhere. Am J Physiol Renal Physiol. 2000, 279:F785-92.
38. Liu G, Kaw B, Kurfis J. Neph1 and nephrin interaction in the slit diaphragm is an important determinant of glomerular permeability. J Clin Invest. 2003, 112:209-21.
39. Kretzler M. Regulation of adhesive interaction between podocytes and glomerular basement membrane. Microsc Res Tech. 2002, 57:247-53.
40. Li JJ, Kwak SJ, Jung DS. Podocyte biology in diabetic nephropathy. Kidney Int Suppl. 2007, S36-S42.
41. Ha H, Hwang IA, Park JH. Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diabetes Res Clin Pract. 2008, 13:S42-5.
42. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991, 40:405-12.
43. Kelly DJ, Aaltonen P, Cox AJ. Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies. Nephrol Dial Transplant. 2002, 17:1327-32.
44. Mifsud SA, Allen TJ, Bertram JF. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia. 2001, 44:878-82.
45. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab. 2008, 4:444-52.
46. Gurley SB, Coffman TM. The renin-angiotensin system and diabetic nephropathy. Semin Nephrol. 2007, 27:144-52.
47. Susztak K, Raff AC, Schiffer M. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 2006, 55:225-33.
48. Hofnagel O, Luechtenborg B, Weissen-Plenz G. Statins and foam cell formation: impact on LDL oxidation and uptake of oxidized lipoproteins via scavenger receptors. Biochim Biophys Acta. 2007, 1771:1117-24.
49. Regoli M, Bendayan M. Alterations in the expression of the alpha 3 beta 1 integrin in certain membrane domains of the glomerular epithelial cells (podocytes) in diabetes mellitus. Diabetologia. 1997, 40:15-22.
50. White JM. ADAMs: modulators of cell-cell and cell-matrix interactions. Curr Opin Cell Biol. 2003, 15:598-606.
51. Millichip MI, Dallas DJ, Wu E. The metallo-disintegrin ADAM10 (MADM) from bovine kidney has type IV collagenase activity in vitro. Biochem Biophys Res Commun. 1998, 245:594-8.
52. Zheng S, Carlson EC, Yang L. Podocyte-specific overexpression of the antioxidant metallothionein reduces diabetic nephropathy. J Am Soc Nephrol. 2008, 19:2077-85.
53. Kim NH, Rincon-Choles H, Bhandari B. Redox dependence of glomerular epithelial cell hypertrophy in response to glucose. Am J Physiol Renal Physiol. 2006, 290:F741-51.
54. Atchley DH, Lopes-Virella MF, Zheng D. Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy. Diabetologia. 2002, 45:1562-71.
55. Coritsidis G, Rifici V, Gupta S. Preferential binding of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells in vitro. Kidney Int. 1991, 39:858-66.
56. Bosmans JL, Holvoet P, Dauwe SE. Oxidative modification of low-density lipoproteins and the outcome of renal allografts at 1 1/2 years. Kidney Int. 2001, 59:2346-56.
57. Ujihara N, Sakka Y, Takeda M. Association between plasma oxidized low-density lipoprotein and diabetic nephropathy. Diabetes Res Clin Pract. 2002, 58:109-14.